Trial Profile
A randomised, double blind, parallel group, comparative Phase I study to evaluate the safety and pharmacokinetics of a single intravenous dose of GB221 compared to Herceptin Registered Trademark (trastuzumab) in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Dec 2019
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- Sponsors Genor Biopharma
- 08 Dec 2011 New trial record